Thrivent Financial for Lutherans Trims Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Thrivent Financial for Lutherans decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 839,461 shares of the medical equipment provider’s stock after selling 28,859 shares during the period. Thrivent Financial for Lutherans owned approximately 0.42% of Zimmer Biomet worth $88,672,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth about $25,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the 3rd quarter worth about $35,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet during the 4th quarter worth about $39,000. Finally, OFI Invest Asset Management acquired a new stake in Zimmer Biomet during the 4th quarter worth about $40,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on ZBH shares. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Finally, Truist Financial restated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Up 0.9 %

ZBH stock opened at $112.78 on Wednesday. The firm has a market cap of $22.45 billion, a PE ratio of 25.34, a PEG ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm’s 50 day moving average price is $106.18 and its 200-day moving average price is $106.88. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm posted $2.20 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.